My basic opinion on Amarin. Like Vascepa, hate management and company structure. My opinion long term is bearish.
Biosciences Delivery Systems+ Antares Chart Update: 5/25/13 $BDSI, $ATRS
My opinion on Antares BDSI pasy trading action and for the future.
I bought BioDelivery Sciences (BDSI) on Bullish Chart: Solid Small Cap Spec Investment.
BioDelivery Sciences (BDSI) focuses on developing and commercializing products in the areas of pain management and oncology supportive care. The company uses its patented BioErodible MucoAdhesive (BEMA) and Bioral cochleate drug delivery technologies in the development of its products. …
Antares Pharma Chart Update and Analysis, May 22
Antares Pharma Chart Update and Analysis, May 22
I bought Antares @ $3.95, I see a move to $4.35 short term
I bought Antares @ $3.95, I see a move to $4.35 short term. I think from tomorrow to beginning of next week, we see the move. From above, we can clearly see a tightening wedge forming in the chart. I…
Insmed Chart technicals with my opinion and explanation: YouTube Video
Insmed Chart technicals with my opinion and explanation: YouTube Video below, enjoy!
Additional Due Diligence on Insmed ($INSM)
• INSM announced their Q4:12 results, ending the quarter with $92.9 million in cash and short-term investments. INSM anticipates that current cash will be sufficient through Phase III CF and NTM trial data and into mid-2014. The company guided to…
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Rally Insmed
The Orphan Drug Act was passed in January 1983 to encourage companies to develop drugs that treat rare medical conditions. Companies that receive Orphan Drug Status gain certain financial incentives such as a longer period of exclusivity, enhanced patent protection,…
Updated: Near-Term Catalysts And High Insider Ownership Make GTx An Attractive Buy
Today, we are going to take a comprehensive look at a small-cap biotech company with several near-term catalysts, a strong cash position, and high insider ownership. I feel with all factors considered, this company can see very good price appreciation…
